skip to Main Content

Canntab Therapeutics Ltd.

CSE: PILL | OTC: CTABF | FSE: TBF1

CAD files All Pills 2019_04_25 v1

We have developed an industry leading product line of hard pill formulations for a variety of cannabinoid (THC & CBD) blends in exacting dosages.

Our proprietary cannabinoid formulations provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication.

CAD files All Pills 2019_04_25 v1

We have developed an industry leading product line of hard pill formulations for a variety of cannabinoid (THC & CBD) blends in exacting dosages.

Our proprietary cannabinoid formulations provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication.

13 Patents Pending in the United States and Canada

covering our proprietary processes and hard pill formulations for,

•Extended Release
•Immediate Release
•Modified-Release Multi-Layer
•Flash-Melt
•Bi-Layered

THE THERAPEUTIC WINDOW

Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop.

Edibles are slow to commence and to subside.

Our solution, an extended release (XR) hard pill with flash melt technology, quickly brings the patient into the therapeutic window and maintains relief.

Canntab Therapeutics Ltd.

THE THERAPEUTIC WINDOW

Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop.

Edibles are slow to commence and to subside.

Our solution, an extended release (XR) hard pill with flash melt technology, quickly brings the patient into the therapeutic window and maintains relief.

Canntab Therapeutics Ltd.

Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada

– Opens the Door for Canadian and International Sales and White Labeling –

Toronto, Ontario — April 23, 2019 — Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the “Company” or “Canntab”) is pleased to announce that by virtue of FSD Pharma Inc. (“FSD”), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a “sale for medical purposes” licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the “FSD Licence”), Canntab is very close to being in a position to sell its products and generate revenue. The FSD License allows Canntab to produce samples of capsules containing CBD and/or THC, which, once approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD’s Health Canada approved facility in Cobourg, Ontario. In addition, the FSD Licence, when combined with an export permit, which FSD intends to acquire as soon as possible, will also allow Canntab to sell its products in foreign markets.

CONTACT US

Interested in what we do? Want to learn more about the opportunties we offer? Get in touch, enter your information and ask any questions you may have. We'll be sure to respond as soon as possible.

THE TEAM

JEFF RENWICK
CEO

• Former President/CEO of Orbus Pharma
• Business Development for Indukern Chemie AG
• Extensive experience in drug formulation and business development

RICHARD GOLDSTEIN
CFO

• Founder of First Republic Capital
• Co-Founder Fraser McKenzie, former EVP and Head of IB at Standard Securities
• With 28 years of experience in Investment Banking, Research, Sales and Trading
• MBA in Finance from McMaster University

TOMMY LAROCQUE
PROCUREMENT

• More than 15 years of experience in Pharmaceuticals
• Previously was Procurement Manager and Compliance officer for Orbus Pharma inc.
• More than 15 year of Pharmaceutical plant GMP construction experience.

ROBERT LEFLER
DIRECTOR OF OPERATIONS

• 25+ years experience in the manufacturing of Pharmaceutical APIs, Finished Doses, Nutraceuticals and Cosmetics.
• Specializes in optimizing processes to allow for scaling up production within a given timeframe, credited with developing 40 lotions and creams.

HAMISH SUTHERLAND
ADVISORY BOARD

• Founding COO of Bedrocan Canada, which was acquired by Tweed, now Canopy, delivering over $400 million in shareholder returns.
• Responsible for first legal transfer of live cannabis plant material from Holland to Canada.
• A professional engineer with an MBA from Schulich.

DR. ERIC HATASHITA
ADVISORY BOARD

• Former Chief Resident, Mt. Sinai Hospital, Toronto.
• Former Family Physician to Saudi Royal Family.
• Founder, Regal Health Services.

BARRY M. POLISUK
CHAIRMAN

• Partner of Garfinkle, Biderman LLP
• Specialized in complex corporate transactions and corporate securities.
• LL.N. cum laude and a Quebec Civil Law degree, both from the University of Ottawa.

VITOR FONSECA
AUDIT COMMITTEE

• Vice President and Treasurer of Rompsen Investment Corp. and former Audit Committee Chair of Enwave Energy Corp.
• Audit Committee Chair of Mission Ready Services.
• MBA, CPA – CGA and member of The Institute of Corporate Directors.

BOB WOLOSCHUK
ADVISORY BOARD

• President of BLM Marketing Management.
• Over 20 years of pharmaceutical executive experience with a successful track record in business development.
• An expert in licensing strategies, both in Canada and international markets.

SABRINA RAMKELLAWAN
ADVISORY BOARD

• Vice President, The Clinical Research Association of Canada.
• President, Canadian Institute for Medical Advancement.
• 20 years experience in clinical trials, including 7 studies on Cannabinoids, establishing her as a leader in the field.

LORNE GERTNER
ADVISORY BOARD

Lorne Gertner has experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry.

Sign up for our monthly newsletter and keep up to date as we move toward product sales in 2019!

Back To Top